University of Rochester Medical Center

Butterfly Network Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Technology, Radiology, Health Technology, Oncology, Medical Devices, Healthcare Reform, Public Policy, Government, Hospitals, Baby, Maternity, Cardiology, Women, Health, Pets, Managed Care, General Health, Veterinary, Nursing, Consumer, Medical Supplies, FDA, Software, Surgery, Hardware, Other Health, Adjustment, University of Rochester Medical Center, Education, NYSE, Fiscal, EBITDA, POCUS, Butterfly network, Bill & Melinda Gates Foundation, Growth, Interest, Network, Ecosystem, Partnership, University, Investment, Access code, Cryptocurrency, Pharmaceutical industry, Video game, Bookkeeping, Butterfly

Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced financial results for the quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced financial results for the quarter ended September 30, 2023, and provided a business update.
  • Forest Neurotech Agreement: On October 24, 2023, Butterfly announced that it had entered into a five-year co-development agreement with Forest Neurotech.
  • Three Months Ended September 30, 2023 Financial Results
    Revenue: Total revenue was $15.4 million, down from $19.6 million in the third quarter of 2022.
  • An explanation of these non-GAAP financial measures is also included below under the heading “Non-GAAP Financial Measures.”
    A conference call to review the third quarter 2023 financial results and provide a business update is scheduled for November 2, 2023, at 4:30 pm Eastern Time.

Duchenne Muscular Dystrophy Added to New York State's Newborn Screening Panel

Retrieved on: 
Wednesday, October 25, 2023
Female, Genetic counseling, Medical genetics, University of Rochester Medical Center, American College, Infant, ACMG, Life, Legislation, NBS, Mentorship, PPMD, Becker muscular dystrophy, Anatomical pathology, Duchenne muscular dystrophy, NYS, Advisory Committee, University, NIH, A.J.K. Mass Communication Research Centre, American College of Medical Genetics and Genomics, Diagnosis, Prognosis, Bangladesh Technical Education Board, Birth control, Pharmaceutical industry, Genomics, Advocacy, Duchenne

WASHINGTON, Oct. 25, 2023 /PRNewswire/ -- In a monumental stride towards improving the lives of children affected by Duchenne muscular dystrophy (Duchenne), Parent Project Muscular Dystrophy (PPMD) proudly announces that Governor Hochul of New York State (NYS) has signed bill S6814/A5042, making Duchenne newborn screening mandatory for all babies born in the state. This remarkable milestone comes after years of dedicated advocacy by PPMD, in collaboration with partners and families, to break down barriers to treatment and care for the Duchenne community.

Key Points: 
  • Another Duchenne Newborn Screening win—every baby born in New York State to be screened for Duchenne muscular dystrophy!
  • WASHINGTON, Oct. 25, 2023 /PRNewswire/ -- In a monumental stride towards improving the lives of children affected by Duchenne muscular dystrophy (Duchenne), Parent Project Muscular Dystrophy (PPMD) proudly announces that Governor Hochul of New York State (NYS) has signed bill S6814/A5042, making Duchenne newborn screening mandatory for all babies born in the state.
  • New York State has paved the path in advancing Duchenne newborn screening, notably through a pilot program carried out from 2019 to 2021.
  • New York State is now the second state, after Ohio, to mandate newborn screening for Duchenne.

Damo Announces the Launch of the DigiM™ Digital Maturity Momentum Awards 2023

Retrieved on: 
Wednesday, October 25, 2023
Momentum, Digital, Virtua Health, University of Rochester Medical Center, Digital Solutions, Self-assessment, Intermountain Health, Organization, Exercise, Senior, Growth, Northwell Health, Ecosystem, University, Benchmarking, Nursing, Video game, Management, Entertainment, Sentara Healthcare

CHICAGO, Oct. 25, 2023 /PRNewswire-PRWeb/ -- Damo Consulting, a prominent player in healthcare digital transformation, is delighted to introduce the highly anticipated DigiM™ Digital Maturity Momentum Awards for 2023. These awards are a testament to the commitment and success of organizations and individuals in the ever-evolving landscape of digital transformation in healthcare.

Key Points: 
  • CHICAGO, Oct. 25, 2023 /PRNewswire-PRWeb/ -- Damo Consulting , a prominent player in healthcare digital transformation, is delighted to introduce the highly anticipated DigiM™ Digital Maturity Momentum Awards for 2023.
  • Last year , our inaugural DigiM™ Digital Maturity Momentum Awards program received an overwhelming response from health systems looking to conduct a self-assessment and compare themselves against their peers in digital transformation progress.
  • The DigiM™ Digital Maturity Momentum Awards are grounded in the DigiM™ Digital Maturity Framework, an invaluable tool for assessing and benchmarking digital maturity and progress within the realm of digital transformation.
  • Why the DigiM™ Digital Maturity Momentum Awards Matter:
    Recognition of Excellence: DigiM™ Award recipients are celebrated for their exceptional leadership in digital transformation, reflecting dedication and accomplishments in the field.

Springbok Analytics announces partnership with Friends of FSH Research

Retrieved on: 
Wednesday, October 18, 2023
Science, 3D, Research, Facial muscles, MRI, Facioscapulohumeral muscular dystrophy, Health, University of Rochester Medical Center, Biomarker, Kennedy Krieger Institute, Johns Hopkins, FSHD, CO, MSK, Seattle Children's, Organization, Inflammation, Edema, HIV disease progression rates, Drug development, Disease, Partnership, DRS, Magnetic resonance imaging, University, University of Kansas Medical Center, NIH, Patient, Hospital, Springbok, Pharmaceutical industry, Medical imaging, Friends

Friends of FSH Research ("Friends") is fully committed to transparent, reproducible, and transformative science that will inspire hope for people living with FSHD.

Key Points: 
  • Friends of FSH Research ("Friends") is fully committed to transparent, reproducible, and transformative science that will inspire hope for people living with FSHD.
  • FSHD is a highly complex and progressive muscle wasting disease which causes weakening and loss of skeletal muscle in adults and children.
  • "We started Friends 20 years ago with the singular mission of stimulating and funding FSHD research in order to find a treatment or a cure.
  • Springbok Analytics reveals never-before-seen data to improve health, performance, treatment monitoring and MSK function.

Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

Retrieved on: 
Monday, October 2, 2023
Nektar, Medical school, Naval Medical Research Center, University, Senior, NKTR, Safety, Efficacy, University School, Nektar Therapeutics, MT, Atopic dermatitis, Washington University School of Medicine, Alopecia areata, University of Washington School of Medicine, Development, Journal of the European Academy of Dermatology and Venereology, Duke University School of Medicine, Patient, SAN, Randomness, Conjugation, University of Rochester Medical Center, Science, University of Bonn, Therapy, Abstract, Queen's University, Treatment, Education, Pharmaceutical industry, Vaccine, PLLC, Dermatology, Regulatory T cell, Venereology, Northwestern University, Medicine

SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, at the 2023 European Academy of Dermatology and Venereology (EADV) Congress to be held October 11-14 in Berlin. REZPEG is in Phase 2 development for the treatment of atopic dermatitis and for the treatment of alopecia areata.

Key Points: 
  • SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, at the 2023 European Academy of Dermatology and Venereology (EADV) Congress to be held October 11-14 in Berlin.
  • REZPEG is in Phase 2 development for the treatment of atopic dermatitis and for the treatment of alopecia areata.
  • "The presentations highlight the momentum and strength of our REZPEG program and, in particular, its potential as a remittive therapy for patients with atopic dermatitis.
  • Sinai, New York, NY, United States; 6Skin Sciences, PLLC, Louisville, KY, United States; 7Rodgers Dermatology, Frisco, TX, United States; 8Nektar Therapeutics, San Francisco, CA, United States; 9Eli Lilly and Company, Indianapolis, IN, United States.

Dr. Jacqueline Lyons Returns to Cross Medical Group

Retrieved on: 
Monday, September 18, 2023
Breast reduction, University, Face, Temple University, Villanova, Quality of life, Woman, Breast augmentation, Laser, Patient, University of Rochester Medical Center, Bryn Mawr, Filler (linguistics), Hand, Female, Veterinary medicine, Dentistry, Nursing

PHILADELPHIA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cross Medical Group, an esteemed practice offering cosmetic surgery for the Philadelphia area , is excited to announced that they have welcomed experienced plastic surgeon Dr. Jacqueline Lyons back to the team this summer.

Key Points: 
  • PHILADELPHIA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cross Medical Group, an esteemed practice offering cosmetic surgery for the Philadelphia area , is excited to announced that they have welcomed experienced plastic surgeon Dr. Jacqueline Lyons back to the team this summer.
  • Dr. Jackie Lyons, who is a Bryn Mawr native, works hand in hand with the practice founder, board-certified plastic surgeon Dr. Kevin Cross.
  • Dr. Lyons specializes in breast surgery and body contouring procedures, including breast augmentation , breast reduction, liposuction, tummy tuck surgery, and Mommy Makeovers.
  • For more information about cosmetic surgery, contact Cross Medical Group.

Annals of Family Medicine: Researchers Describe Clinical Experiences of Transgender People, Recommend Strategies to Reduce Negative Health Consequences

Retrieved on: 
Monday, September 18, 2023
Medicalization, Annals of Family Medicine, Society, University, College, Physician, Curriculum, Empowerment, Yale Cancer Center, American Academy, North American Primary Care Research Group, Research, Multimedia, American Board of Family Medicine, American Board of Commissioners for Foreign Missions, Stigma, Family medicine, Patient, University of Rochester Medical Center, College of Family Physicians of Canada, American Academy of Family Physicians, Assault, Teacher, Safety, Nursing, Pharmaceutical industry, Annals

A new paper published in the September/October 2023 issue of Annals of Family Medicine describes the clinical experiences of transgender people.

Key Points: 
  • A new paper published in the September/October 2023 issue of Annals of Family Medicine describes the clinical experiences of transgender people.
  • Study authors also present short-term and long-term strategies towards reducing oppression and its health consequences among this patient population.
  • "Understanding the experiences of transgender people when their gender identities are known to clinicians and the reasons transgender people may share, modify, or withhold information could yield important clinical insights," the authors write.
  • Annals of Family Medicine is a peer-reviewed, indexed research journal that provides a cross-disciplinary forum for new, evidence-based information affecting the primary care disciplines.

LogicSource Announces Emerging Healthcare Leadership Team

Retrieved on: 
Tuesday, August 29, 2023
Boston Children's Hospital, University, Senior, AUC, EY, Radiology, Owens & Minor, Negotiation, Pharmacy, MedStar Health, Lifespan, CFOS, History of the University of Maryland, College Park, Organization, Cardinal Health, Ernst & Young, University of Rochester Medical Center, Philips, Growth, Hospital, Financial management, Nursing, Management, Health care

Forming LogicSource's healthcare leadership are Mark Van Sumeren, General Manager of Healthcare; David Kirshner, Managing Partner of Healthcare; and Susan Tyler, Managing Director of Healthcare.

Key Points: 
  • Forming LogicSource's healthcare leadership are Mark Van Sumeren, General Manager of Healthcare; David Kirshner, Managing Partner of Healthcare; and Susan Tyler, Managing Director of Healthcare.
  • "We are thrilled to announce the leadership team we've assembled to address some of the most pressing and urgent issues around non-clinical procurement and margin improvement in healthcare," said David Pennino, CEO and founder of LogicSource.
  • Mark Van Sumeren joins LogicSource as the General Manager of Healthcare and is a veteran healthcare executive with a decades-long career in healthcare strategy, operations, and supply chain.
  • Susan brings a wealth of healthcare and supply chain experience to the LogicSource team.

Delphinus Medical Technologies Raises $12 Million as Footprint Continues to Expand

Retrieved on: 
Tuesday, August 22, 2023
Oncology, Medical Devices, Health, Health Technology, Radiology, Biotechnology, Trinity, Health technology, Innovation system, Cancer, Woman, Breast, Research, University of Rochester Medical Center, Patient, Investment, Risk, University, Growth, FDA, Breast cancer, Pharmaceutical industry, Medical imaging, Delphinus

Delphinus Medical Technologies , the pioneers of dense breast medical imaging, announced today that it raised $12 million in growth capital from Trinity Capital Inc. (NASDAQ: TRIN), a leading provider of diversified financial solutions to growth-stage companies.

Key Points: 
  • Delphinus Medical Technologies , the pioneers of dense breast medical imaging, announced today that it raised $12 million in growth capital from Trinity Capital Inc. (NASDAQ: TRIN), a leading provider of diversified financial solutions to growth-stage companies.
  • This disruptive technology not only redefines the standards for early breast cancer detection, but also enhances patient comfort, and reduces unnecessary callbacks.
  • “Mammography alone is not enough to address the screening needs of dense breast patients,” said Mark J. Forchette, president and CEO of Delphinus Medical Technologies.
  • Delphinus continues to expand its commercial foundation, most recently adding Corewell Health to the roster of clinical sites that are building robust dense breast screening programs to benefit patients.

TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

Retrieved on: 
Wednesday, August 16, 2023
Surgeon, PRS, Anatomy, Weakness, Permeability, Patient, University of Rochester Medical Center, 3D printing, Dentistry, MD

OviTex PRS Long-Term Resorbable is intended for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.

Key Points: 
  • OviTex PRS Long-Term Resorbable is intended for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.
  • OviTex PRS Long-Term Resorbable supplements the Company's existing OviTex PRS portfolio, which includes OviTex PRS Permanent and OviTex PRS Short-Term Resorbable configurations.
  • OviTex PRS Long-Term Resorbable enhances the OviTex PRS portfolio with specific design features, including bi-directional stretch and a fully resorbable, long-term polymer for reinforcement.
  • “We are excited to offer expanded clinical utility of the OviTex PRS portfolio to surgeons and patients in plastic and reconstructive surgery,” said Antony Koblish, President and CEO of TELA Bio.